Active	Status	Sponsor type	Region	Phase	Filter
27 Active 1 Inactive 28 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

26 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Sonwalkar, Sunil
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1	Recruiting	3	612	Europe, Canada, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
ABTECT, NCT05535946: - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	01/30
Gawdis-Wojnarska, Beata
NCT04779320 / 2020-004301-31: A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)	Recruiting	3	120	Europe, Canada, Japan, US, RoW	Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002	Takeda, Takeda Development Center Americas, Inc.	Crohn's Disease (CD)	11/24	11/24
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis	Active, not recruiting	3	160	Europe, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Ulcerative Colitis, Ulcerative Colitis Chronic	08/24	09/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	Recruiting	3	778	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Crohn's Disease	11/24	12/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis	Recruiting	3	1063	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Ulcerative Colitis	07/26	12/27
MLN0002-3024, NCT04779307 / 2020-004300-34: A Study of Vedolizumab in Children and Teenagers with Moderate to Severe Ulcerative Colitis (UC)	Active, not recruiting	3	121	Europe, Canada, Japan, US, RoW	Vedolizumab, MLN0002, ENTYVIO, KYNTELES	Takeda, Takeda Development Center Americas, Inc.	Colitis, Ulcerative	08/25	08/25
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis	Recruiting	3	60	Europe, Canada, Japan, US, RoW	Mirikizumab IV, LY3074828, Mirikizumab SC	Eli Lilly and Company	Ulcerative Colitis	07/26	03/27
SHINE-ON, NCT04844606 / 2020-005311-49: A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease	Recruiting	3	150	Europe, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company, Eli Lilly and Company	Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease	07/30	07/30
NCT05442567 / 2021-000630-34: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)	Recruiting	3	240	Europe, Canada, Japan, US, RoW	Vedolizumab IV, MLN0002, ENTYVIO, KYNTELES, No Intervention	Takeda, Takeda Development Center Americas, Inc.	Ulcerative Colitis, Crohn's Disease	08/31	08/31
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease	Recruiting	2	268	Europe, Canada, Japan, US, RoW	TAK-279, Zasocitinib, Placebo	Takeda	Crohn's Disease	09/26	07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis	Recruiting	2	207	Europe, Canada, Japan, US, RoW	TAK-279, Zasocitinib, Placebo	Takeda	Ulcerative Colitis	09/26	08/27
Gehring, Stephan
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis	Recruiting	3	60	Europe, Canada, Japan, US, RoW	Mirikizumab IV, LY3074828, Mirikizumab SC	Eli Lilly and Company	Ulcerative Colitis	07/26	03/27
SHINE-ON, NCT04844606 / 2020-005311-49: A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease	Recruiting	3	150	Europe, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company, Eli Lilly and Company	Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease	07/30	07/30
Kempinski, Radoslaw
VERDICT, NCT04259138 / 2019-002485-12: Determination of the Optimal Treatment Target in Ulcerative Colitis	Active, not recruiting	4	672	Europe, Canada, US, RoW	Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C	Alimentiv Inc., Takeda Development Center Americas, Inc.	Colitis, Ulcerative	03/26	03/26
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1	Recruiting	3	612	Europe, Canada, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis	Active, not recruiting	3	160	Europe, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Ulcerative Colitis, Ulcerative Colitis Chronic	08/24	09/25
ABTECT, NCT05535946: - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	01/30
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis	Recruiting	3	60	Europe, Canada, Japan, US, RoW	Mirikizumab IV, LY3074828, Mirikizumab SC	Eli Lilly and Company	Ulcerative Colitis	07/26	03/27
Wojnarska, Beata Gawdis
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1	Recruiting	3	612	Europe, Canada, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
ABTECT, NCT05535946: - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	01/30
Liszka-Dalecki, Piotr
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1	Recruiting	3	612	Europe, Canada, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
ABTECT, NCT05535946: - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	01/30
Hensel, Kai
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis	Recruiting	3	60	Europe, Canada, Japan, US, RoW	Mirikizumab IV, LY3074828, Mirikizumab SC	Eli Lilly and Company	Ulcerative Colitis	07/26	03/27
SHINE-ON, NCT04844606 / 2020-005311-49: A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease	Recruiting	3	150	Europe, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company, Eli Lilly and Company	Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease	07/30	07/30
Knafelz, Daniela
SHINE-2, NCT05784246: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis	Recruiting	3	60	Europe, Canada, Japan, US, RoW	Mirikizumab IV, LY3074828, Mirikizumab SC	Eli Lilly and Company	Ulcerative Colitis	07/26	03/27